The present invention relates to compounds of formula I
wherein
R, R1, R2, R3, R4, aryl, n, and m are as defined in the specification and pharmaceutically acceptable acid addition salts and tautomeric forms thereof. Such compounds have good activity on the 5-HT5A receptor. Therefore, the invention provides methods for the treatment of certain CNS disorders with such compounds.
The present invention relates to compounds of formula I
wherein
R, R
1
, R
2
, R
3
, R
4
, aryl, n, and m are as defined in the specification and pharmaceutically acceptable acid addition salts and tautomeric forms thereof. Such compounds have good activity on the 5-HT
5A
receptor. Therefore, the invention provides methods for the treatment of certain CNS disorders with such compounds.